HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms
Objective : To determine the efficacy of three doses of a new , oral formulation of estradiol acetate ( EA ) for alleviation of vasomotor and urogenital symptoms in postmenopausal women . Design : Two separate 12-week studies were undertaken in postmenopausal women with moderate to severe vasomotor symptoms . In the first study , women were r and omly assigned to EA 0.9 mg/day , EA 1.8 mg/day , or placebo  ( study 1 ; N = 293 ) , and in the second study to oral EA 0.45 mg/day or placebo  ( study 2 ; N = 259 ) . Women recorded the frequency and severity of vasomotor symptoms daily and urogenital symptoms weekly on diary cards . Investigators assessed signs of vaginal atrophy . Results : Frequency of moderate to severe vasomotor symptoms decreased significantly versus placebo , starting at week 2 in the EA 1.8-mg group ( P = 0.005 ) , week 3 in the EA 0.9-mg group ( P = 0.003 ) , and week 6 in the EA 0.45-mg group ( P < 0.05 ) . At week 12 , mean percent reduction from baseline in vasomotor-symptom frequency was 91 % , 78 % , and 61 % , respectively . Vasomotor-symptom severity decreased significantly versus placebo , starting at weeks 2 and 3 with EA 1.8 mg and 0.9 mg , respectively , and at week 5 with EA 0.45 mg . Vaginal pH and maturation index improved significantly in all EA groups versus placebo , and some signs and symptoms of vaginal atrophy improved at the EA 0.9- and 1.8-mg doses . Side effects were mild to moderate and consistent with estrogen therapy . Conclusions : Oral EA at all doses was well tolerated and significantly reduced the frequency and severity of postmenopause symptoms versus placebo
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .